- For Immediate Release:
Today, the U.S. Food and Drug Administration announced it has awarded 11 new clinical trial research grants, equaling more than $25 million of funding over the next four years. The FDA’s Congressionally-funded Orphan Products Grants Program awards these grants to clinical investigators to support the development of medical products for patients with rare diseases.
“Supporting the development and evaluation of new treatments for rare diseases is a critical part of the FDA’s mission,” said Acting FDA Commissioner Janet Woodcock, M.D. “These grants are the latest examples of the FDA’s ongoing commitment to help meet the future and current health needs of those who suffer from a rare disease.”
The grant awards support clinical studies of products that address unmet needs in rare diseases or conditions or provide highly significant improvements in treatment or diagnosis.
Many of these studies involve children as young as infants. One of them is evaluating treatment for a rare inherited skin condition called recessive dystrophic epidermolysis Bullosa. This condition can cause painful blisters and disfiguring wounds that can be fatal. A second study aims to assess the effectiveness of early treatment for infants with tuberous Sclerosis Complex, an inherited condition that can cause seizures and other long-term brain problems. The grant includes an innovative demonstration project, which will use a collaborative approach to assess a tool that could improve data accuracy in clinical trials occurring at multiple locations.
Some of the new awards will fund clinical trials of products that can be used in brain cancer treatment. One will be evaluating a novel peptide vaccine for treating pediatric brain cancers. This vaccine targets specific areas of brain tumors and could have a significant impact on how these rare and dangerous tumors are treated.
“The Office of Orphan Products Development works to identify, examine and ultimately fill the gaps that exist within the rare disease drug development community by funding necessary and revolutionary clinical studies to determine the safety and efficacy of potential treatment options,” said Sandra Retzky, D.O., J.D., MPH, director of OOPD. “These grants demonstrate the FDA’s commitment to supporting the development of new treatments for patients living with rare diseases.”
Below is a complete list of the grants in alphabetical order:
- Armgo Pharma, INC. (Ardsley, New York); Eugene Marcantonio; Phase 2 study of S48168 (ARM210) for the treatment of catecholaminergic polymorphic ventricular tachycardia type 1 (CPVT1); $1 million over two years
- Boston Children’s Hospital (Boston, Massachusetts); Mark Puder; Phase 3 study of RELiZORB for the treatment of short bowel syndrome; $2.7 million over four years
- Castle Creek Biosciences, LLC (Exton, Pennsylvania); Mary Spellman; Phase 3 study of FCX-007 (genetically modified autologous human dermal fibroblasts) for the treatment of recessive dystrophic epidermolysis bullosa; $1.8 million over four years
- Cincinnati Children’s Hospital Medical Center (Cincinnati, Ohio); Darcy Krueger; Phase 2b study of sirolimus for the prevention of epilepsy in patients with tuberous sclerosis complex; $5 million over four years
- Cincinnati Children’s Hospital Medical Center; Michael Jordan; Phase 2 study of abatacept for the treatment of common variable immunodeficiency with interstitial lung disease (ABCVILD); $3.1 million over four years
- Duke University (Durham, North Carolina); Eric Thompson; Phase 2 study of peptide vaccine targeting CMV antigen for the treatment of newly diagnosed pediatric high-grade glioma and diffuse intrinsic pontine glioma and recurrent medulloblastoma; $1.8 million over four years
- Massachusetts General Hospital (Boston, Massachusetts); Amy Dickey; Phase 2 study of oral cimetidine for the treatment of protoporphyrias; $1.6 million over four years
- Mayo Clinic Rochester (Rochester, Minnesota); Sani Kizilbash; Phase 1 study of WSD0922-FU for the treatment of high-grade astrocytoma; $1 million over three years
- Mayo Clinic Rochester (Rochester, Minnesota); Wolfgang Singer; Phase 2 study of intrathecally administered autologous mesenchymal stem cells for the treatment of multiple system atrophy; $3.2 million over four years
- Reveragen Biopharma, Inc.; Eric Hoffman; Phase 2a study of vamorolone for the treatment of becker muscular dystrophy; $1.2 million over two years
- University of Florida (Gainesville, Florida); Peter Stacpoole; Phase 2A trial of dichloroacetate for the treatment of glioblastoma multiforme; $2.5 million over four years
As challenges and increased costs continued this year for clinical trials due to the COVID-19 pandemic, the FDA remains committed to supporting rare disease research by providing existing grantees with additional funding. The FDA provides funding to existing grantees to support ongoing research. This allows them to take the necessary steps to ensure that their studies can continue.
The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. It is also responsible for the safety of the nation’s food supply, cosmetics, dietary supplement, and products that emit electronic radiation.
ALISO VIEJO, Calif.–(BUSINESS WIRE)–BrainChip Holdings Ltd (ASX: BRN), (OTCQX: BRCHF), a leading provider of ultra-low power high performance artificial intelligence technology, today announced that Chief Development Officer Anil Mankar will present “Intelligent Edge AI: The Future is Now” at the Linley Fall Processor Conference 2021 in the Hyatt Regency Hotel in Santa Clara, California, October…
Artificial intelligence (AI), which has seen rapid growth over the past few years, is mainly due to the development of deep neural networks and artificial intelligence computing technology. Experts believe that there will come a time when artificial intelligence will exceed human intelligence, or be able to do many tasks better than humans.
WASHINGTON – As part of its mission to recruit diverse cybersecurity talent and build the workforce of the future, the Cybersecurity and Infrastructure Security Agency (CISA) has awarded $2 million to two innovative organizations for development of cyber workforce training programs. The NPower and CyberWarrior organizations, which received the awards, will focus on the unemployed…
Russian online bank Tinkoff has launched an e-commerce venture. The new platform, a constellation of services and tools designed to help entrepreneurs handle and boost their online sales, will cater to a rapidly expanding online economy in Russia, as well as to clients hoping to grow their international presence. Tinkoff has hired Ilya Kretov, formerly…
Most Popular Articles on dWeb.News
- HEALTH NEWS: Major Insurers Are Running Billions of Dollars Behind in Payments to Doctors and Hospitals
- RUSSIA NEWS: Putin Says NATO’s Military Presence in Ukraine Poses Threat to Russia
- Top 10 Killer Magento SEO Tips for Your E-Commerce Website
- HEALTH NEWS: Eco-Rooted Lawsuits Target Needle Exchanges. This will be stopped by a new California law.
- RUSSIA NEWS: Taliban welcomes Russia’s plans to remove them form the terrorist list
- ISRAEL NEWS: Austrian leader said to cancel Israel visit amid corruption allegations